Investment Thesis
AMGEN demonstrates strong fundamental operations with robust 10% revenue growth, exceptional 88.2% EPS growth, and industry-leading profit margins (55% gross, 30.9% operating). However, the elevated debt-to-equity ratio of 6.24x and interest coverage of 4.1x introduce meaningful leverage risk that warrants caution despite solid free cash flow generation of $1.5B.
Strengths
- Exceptional EPS growth of 88.2% YoY with 10% revenue growth demonstrates operational leverage and margin expansion
- Industry-leading profitability with 55% gross margin and 30.9% operating margin indicating strong pricing power and operational efficiency
- Robust free cash flow generation at $1.5B annually (17.1% FCF margin) with solid operating cash flow of $2.2B provides financial flexibility and capital allocation options
- Strong ROE of 19.8% demonstrates effective use of shareholder capital
- Substantial cash position of $12.0B provides liquidity buffer for operations and M&A
Risks
- Dangerously high debt-to-equity ratio of 6.24x indicates excessive financial leverage and elevated refinancing risk
- Interest coverage ratio of 4.1x leaves limited cushion for earnings deterioration or rising interest rates
- Low ROA of 2.0% despite $92.5B asset base suggests capital efficiency concerns or asset impairment risks
- Biotech/pharma sector exposure to patent cliffs, regulatory changes, and pricing pressure from policymakers
- R&D-dependent business model requiring continuous innovation with uncertain pipeline success rates
Key Metrics to Watch
- Debt-to-equity ratio trajectory and deleveraging progress
- Operating cash flow sustainability and free cash flow margins
- Interest coverage ratio and debt service capacity amid rate environment changes
- Pipeline advancement and R&D productivity metrics
- Revenue growth sustainability and market share trends in key therapeutic areas
Financial Metrics
Revenue
8.6B
Net Income
1.8B
EPS (Diluted)
$3.34
Free Cash Flow
1.5B
Total Assets
92.5B
Cash
12.0B
Profitability Ratios
Gross Margin
55.0%
Operating Margin
30.9%
Net Margin
21.1%
ROE
19.8%
ROA
2.0%
FCF Margin
17.1%
Balance Sheet & Liquidity
Current Ratio
1.26x
Quick Ratio
1.01x
Debt/Equity
6.24x
Debt/Assets
0.0%
Interest Coverage
4.06x
Long-term Debt
57.3B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T16:52:00.724041 |
Data as of: 2026-03-31 |
Powered by Claude AI